ArticleThe American journal of pathology2026
Silencing Ubiquitin-Specific Peptidase 10 Alleviates Persistent Corneal Epithelial Defect in Mice.
Article in The American journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Persistent corneal epithelial defect is a condition in which the corneal epithelium fails to heal properly after injury, resulting in vision loss. Previous studies demonstrate that the deubiquitinase, ubiquitin-specific peptidase 10 (USP10), is a key regulator of wound healing and scarring in the cornea. Here, a highly modified in vivo self-delivering siRNA (sdRNA) targeting USP10 in a mouse model of persistent corneal epithelial defect was used. In this model, the corneal epithelium is scraped from the basement membrane and, although the wound initially closes, the epithelium re-opens at day 28, thereby modeling a persistent corneal defect. These studies revealed that one dose of USP10-targeting sdRNA after wounding prevented re-opening of the wound at day 28. Optical coherence tomography images, hematoxylin and eosin staining, and immunohistochemistry demonstrated improved corneal morphology and normal epithelial stratification of the regrown epithelium, with re-establishment of hemidesmosomes and reduced scarring and inflammation (CD45
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.